论文部分内容阅读
目的探讨地特胰岛素或精蛋白生物合成人胰岛素(NPH)联合门冬胰岛素治疗2型糖尿病患者的疗效。方法血糖控制欠佳的2型糖尿病患者120例,随机分成对照组和试验组,每组60例。对照组予NPH睡前皮下注射联合门冬胰岛素三餐前皮下注射,试验组予地特胰岛素睡前皮下注射联合门冬胰岛素三餐前皮下注射。监测患者每日血糖情况和不良反应。结果试验组血糖达标时间为(5.0±2.0)d,短于对照组[(7.0±2.5)d,P<0.05],试验组胰岛素最终剂量为(22.11±13.13)U,低于对照组[(29.22±9.76)U,P<0.05]。试验组血糖总标准差低于对照组[(1.28±0.48)mol.L-1vs.(1.94±0.95)mol.L-1,P<0.05],两组血糖变异系数无显著差异(P>0.05),低血糖发生率无显著差异(P>0.05)。结论地特胰岛素联合门冬胰岛素治疗血糖控制欠佳的2型糖尿病,血糖控制疗效与NPH联合门冬胰岛素相当,血糖达标快、胰岛素用量少、血糖更平稳。
Objective To investigate the effect of insulin detemir or protamine biosynthesis of human insulin (NPH) combined with insulin aspart in type 2 diabetic patients. Methods A total of 120 type 2 diabetic patients with poor glycemic control were randomly divided into control group and experimental group with 60 cases in each group. The control group was injected subcutaneously with NPH before bedtime and insulin aspart before subcutaneous injection, and the experimental group was given subcutaneous injection of detemir before bedtime and subcutaneous injection of insulin aspart before meals. Monitor daily blood glucose and adverse reactions. Results The blood glucose level of the experimental group was (5.0 ± 2.0) d, shorter than that of the control group [(7.0 ± 2.5) d, P <0.05]. The final dose of insulin in the experimental group was (22.11 ± 13.13) 29.22 ± 9.76) U, P <0.05]. The total standard deviation of blood glucose in the experimental group was significantly lower than that in the control group [(1.28 ± 0.48) mol.L-1vs. (1.94 ± 0.95) mol.L-1, P <0.05] ), No significant difference in the incidence of hypoglycemia (P> 0.05). Conclusion Dextrins plus insulin aspart in the treatment of type 2 diabetes with poor glycemic control. The efficacy of glycemic control is comparable with that of NPH plus insulin aspart, the fasting blood glucose standard, less insulin dosage and more stable blood glucose.